We are investigating SteadyMed Ltd. (“STDY”) (“SteadyMed” or the “Company”) relating to the sale of the Company to United Therapeutics Corporation. (“UTHR”). Under the terms of the transaction, SteadyMed shareholders will receive $4.46 in cash and an additional $2.63 in cash upon achievement of certain milestone related to SteadyMed’s Trevyent drug-device combination product for each share of SteadyMed stock they own.